A Phase 1/2, Open-label Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy
Latest Information Update: 23 Jul 2025
At a glance
- Drugs BBM D101 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors Belief Biomed
Most Recent Events
- 23 Jul 2025 New trial record